Form 4: Humacyte Director Acquires 50,000 Stock Options
SEC Form 4 Filing
Susan Richards Windham-Bannister, a director of Humacyte, Inc., acquired 50,000 stock options on June 13, 2024, exercisable over a four-year period.
Summary
- On June 13, 2024, Susan Richards Windham-Bannister, a director of Humacyte, Inc., acquired 50,000 stock options.
- The exercise price of these options is $7.20.
- The options become exercisable starting June 13, 2025, with 25% vesting initially.
- The remaining options vest monthly until June 13, 2028.
- The options expire on June 13, 2034.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing the acquisition of stock options by a company director. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.
Stakeholder Impact
- The acquisition of stock options by a director could be seen as a positive sign by shareholders, indicating confidence in the company's future performance.
Key Dates
| Date | Description |
|---|---|
| 06/13/2024 | Date of transaction: Director acquired 50,000 stock options. |
| 06/13/2025 | First 25% of the options become exercisable. |
| 06/13/2028 | Options fully vested. |
| 06/13/2034 | Expiration date of the stock options. |
| 06/17/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.